

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT APPROVAL OF INTRAROSA BY NMPA

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Lee's Pharmaceutical Holdings Limited (the “**Company**” or “**Lee's Pharm**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that, on 17 March 2026, the National Medical Products Administration of China (“**NMPA**”) has granted approval for Intrarosa, a product owned by Cosette Pharmaceuticals and licensed to Lee's Pharm, for the treatment of postmenopausal women with moderate to severe vulvovaginal atrophy symptoms, excluding urinary symptoms.

This approval marks a significant milestone following the successful completion of the Phase III, multicenter, randomised, double-blinded, parallel-group clinical trial conducted by Zhaoke Pharmaceutical (Hefei) Company Limited, a wholly-owned subsidiary of the Company.

ABOUT INTRAROSA

Intrarosa is the only FDA and EMA approved, locally administered, daily non-estrogen steroid for the treatment of moderate to severe dyspareunia (pain during intercourse), a symptom of vulvovaginal atrophy due to menopause. Intrarosa contains prasterone (dehydroepiandrosterone, DHEA), an inactive endogenous steroid converted locally into androgens and estrogens to help restore vaginal tissue.

ABOUT LEE'S PHARM

Lee's Pharm is a research-driven and market-oriented biopharmaceutical company with more than 30 years of operation in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with numerous international companies in the U.S., EU, and Asia, and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key disease therapeutic areas such as cardiovascular health, woman's health, paediatrics, rare diseases, oncology, dermatology and obstetrics. In addition, the Company has recently acquired U.S.-based assets in line with its strategy to broaden its portfolio of innovative drug delivery technologies covering a wide range of indications and reinforcing the Company's global expansion strategy. More information is available at www.leespharm.com.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 25 March 2026

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive Directors; Dr. Li Xiaoyi, Mr. James Charles Gale and Mr. Huang Zuie-Chin are non-executive Directors; and Dr. Chan Yau Ching, Bob, Ms. Cheang Yee Wah, Eva and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.

* For identification purpose only